Most patients with Hodgkin lymphoma (HL) get a remission after induction chemotherapy
with or without radiation therapy (RT). However, relapse rates range from 10–20% in cases …

The programmed death-1 (PD-1) regulatory pathway is active in several tumors and a potent
immunotherapeutic target with PD-1 inhibitors. Nivolumab is an anti-PD-1 monoclonal …

TPS7573 Background: Nivo is a human IgG4 monoclonal antibody immune checkpoint
inhibitor that targets programmed death receptor-1 (PD-1) on activated immune cells and …

Objectives Cancer can escape the immune system through different mechanisms. One such
mechanism is the expression of program death ligand-1 which binds to PD-1 receptor on …

Cancer can escape the immune system through different mechanisms. One of which is the
expression of program death ligand-1 (PD-L1). This ligand binds to programmed cell death …

Objective To report the first experience with Nivolumab in the management of patients with
R/R cHL in Slovakia. Design Retrospective analysis of patients with R/R cHL who received …

Background Many patients with classical Hodgkin lymphoma show increased programmed
death-1 ligand expression in Reed–Sternberg cells. We report the final results of a phase II …

Background CT and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT performances
following immune therapy are not well known in patients with relapsed or refractory Hodgkin …

The paradigm of response in Hodgkin lymphoma (HL) was developed in cytotoxic
chemotherapies and its use as a reference model for immune-modulatory regimens, which …

Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in
approximately one-third of the responding patients, the disease relapses following …